Monthly Archives: July 2021

The University of Wisconsin School of Medicine and Public Health will be the first site to host a new national fellowship that aims to makethe doctor's office more supportive ofLGBTQ patients.

The school will receive $750,000 over four years from the American Medical Association Foundation to launch a training program for early-career primary care physicians to ensureLGBTQ people have access to a high standard of health care.

Research has shown that discrimination against LGBTQ people is associated with higher rates of depression, increased suicide risk and reduced access to preventive health caresuch as cancer screenings.

In the past year, 15% of LGBTQ Americans postponed needed medical care for fear of discriminationfrom their health care provider, according to an October 2020 study from the Center for American Progress, a progressive think tank based in Washington, D.C.

Many LGBTQ respondents have had other negative experiences with health care, the study found, including a provider being visibly uncomfortable with their sexual orientation (14% of respondents), harsh or abusive language (8%) or unwanted physical contact (7%).

The outlook is worse for transgender people a third of whom in the same study reported having to teach their provider about transgender people to receive appropriate care and LGBTQ people of color, who often experience intersecting discrimination.

These results track locally: A 2019 study using data from the Survey of the Health of Wisconsin found lesbian, gay and bisexual Wisconsinites were twice as likely as their heterosexual counterparts to delay obtaining health care, and transgender residents were nearly three times more likely to report poor quality of care and unfair treatment by the medical profession.

RELATED:New UW clinic to use latest genetic technology to help patients with unknown diseases

RELATED:Pride across a century: A look at the LGBTQ history of Wisconsin

UW-Madison's fellowship program aims to turn those outcomes around. And while it's first, the foundation'swebsite says it plans to support fellows at dozens of institutions over the next decade.

Dr. Elizabeth Petty, senior associate dean for academic affairs at the School of Medicine and Public Health, will serve as program director.

As a lesbian woman, Petty said she hashad some negative encounters with the health care system.

"I've had some things that were said that were offensive or humiliating, things that were wrong in terms of making assumptions about my sexual activity ... not offering the kind of care I knew I needed as a physician," she said.

She's also part of Facebook groups for LGBTQ people in Madison to share which doctors will provide affirming care and which to avoid. It upsets her that affirmingcare isn't a given.

The fellows who take part in this program are expected to help changethat landscape. Petty said they plan to recruit nationally for early-career primary care providers who have a track record of health equity work.

The first year of the program, which will kick off in July 2022, will serve as a pilot year, with the goal of adding three fellows per year as its reputation grows.

It will be housed within the school's Department of Family Medicine and Community Health, andfellows will do both clinical and classroom training in LGBTQ health topics and participate in research, teaching, mentoring and community engagement.

Research in particular will be critical to improving health outcomes for LGBTQ people, Petty said, because there's so much left to be explored: the unique needs in rural communities, across intersections of race and ethnicity, and across a person's lifespan, to name a few.

When fellowships conclude, doctors will have a variety of options at their fingertips, she said. They could stay on to do research or teach at UW, join a practice elsewhere in Wisconsin or even go on to be a "change agent" at the national level.

Petty said it's exciting to be the first school chosen for the fellowship program, but that it's even more exciting to picture a few years down the road, when theremight be a strong network of programs improving the health care experiencefor LGBTQ patients across the country.

In Wisconsin, she feels the work will tie directly to the Wisconsin Idea the notion that what's learned at the university should be applied to solve problems throughout the state.

"We can change the shape of health care for LGBTQ people," she said. "We're here to serve."

Contact reporter Madeline Heim at 920-996-7266 or mheim@gannett.com. Follow her on Twitter at @madeline_heim.

The rest is here:
LGBTQ patients face bias at the doctor's office. Here's how a first-of-its-kind fellowship at UW medical school aims to change that. - Appleton Post...

Tessara Therapeutics Cambridge, Mass.-based Tessara Therapeutics tapped Howard Liang as president and chief executive officer. Additionally, the company also expanded its leadership team with multiple appointments. Madhusudan Peshwa was named Chief Technology Officer for Cell Therapy;Bill Querbes was tapped as Senior Vice President of Therapeutic Discovery & Translational Sciences; Cecilia Cotta-Ramusino was promoted to Senior Vice President of Platform Development; Vikram Ranade was named Senior Vice President of Corporate Development; David Pollard was named Head of Bioprocess, and Steve Garbacz was tapped as Head of Finance. Prior to joining Tessara, Liang was Chief Financial Officer and Chief Strategy Officer at BeiGene for six years.

Before BeiGene, Liang spent 10 years at Leerink Partners, where he was Managing Director and Head of Biotechnology Equity Research. Peshwa joined Tessara in May 2021 after serving as CTO at Mana Therapeutics Peshwa is responsible for developing the strategy and executing the operating plan encompassing the design, development, and manufacture of Tessaras proprietary mobile gene element engineered cell therapy product portfolio. Bill Querbes joined Tessara in April of 2021 as Senior Vice President of Therapeutic Discovery and Translational Sciences. Before that, he held the position of Vice President and Fabry Program Lead at AVROBIO. Cecilia Cotta-Ramusino joined Tessara in 2019 as the Head of Platform Development. Cotta-Ramusino was the first employee at insitro where she was the Head of Functional Genomics. Prior to insitro, she was one of the first scientists hired at Editas.Ranade joined Tessara in 2020 as the Head of Corporate Development.

In this role, he drives corporate strategy, business development, and investor relations for Tessara. He was previously at McKinsey & Company, where he was an Associate Partner in the healthcare practice. Pollard, the head of Bioprocess, has over 25 years of bioprocess development. He has held roles at Merck & Co. and Sartorius. Pollard will help Tessara drive digital workflows and high throughput automation to accelerate sustainable gene therapy process development. Steve Garbacz joined Tessara in 2021 as the Head of Finance. He has more than 25 years of experience in financial management for a range of companies, including Biogen, Epizyme, Spero, and Anika.

AbCellera Neil Berkley has been named Chief Business Officer of AbCellera. Berkleys role will include leading the strategy and continued growth of AbCelleras partnership business, which currently includes a diverse portfolio of more than 100 programs with drug developers of all sizes. He joins AbCellera from Halozyme Therapeutics, where he served as Vice President, Head of Business Development. Berkley held leadership roles at Axerovision, COI Pharmaceuticals, Acadia Pharmaceuticals, Cadence Pharmaceuticals, and GSK. He also cofounded Mpex Pharmaceuticals, which was acquired by Aptalis, and Vaxiion, a clinical stage bladder cancer company.

Pierre Fabre Francesco Hofmann was appointed Head of R&D at Pierre Fabre Medical Care. Hofmannwilloversee theGroup's innovation strategy for pharmaceuticals (oncology, dermatology, rare diseases, health care). Before joining the Pierre Fabre Group, Hofmann had been workingas Global Head of Oncology Drug Discoveryfor Novartis. In this leadership role, hecoordinatedthe discovery andprogression intoclinical development of no less than twelve new cancer drugs. Hofmann'sprimarymission will be toaccelerate the delivery of new therapeuticstodevelop the Group's R&D portfolio in pharmaceuticals, through a combination of in-house projects and external partnership opportunities.

Sherlock Biosciences Bryan Dechairo was named president and CEO of Cambridge, Mass.-based Sherlock. He succeeds co-founder Rahul Dhanda, who willcontinue to serve as a board member until the end of 2021 and then as strategic adviser in 2022.Dechairo joins Sherlock from Myriad Genetics, where he was executive vice president of clinical development. Before joining Myriad, he was CMO, chief scientific officer and senior vice president of research and development at Assurex Health, which was acquired by Myriad in 2016. Prior to Assurex Health, Dechairo held roles of increasing responsibility at Medco Health Solutions, Pfizer and other diagnostic and therapeutics companies.

Atsena Therapeutics Jennifer Wellman was appointed to the board of directors of N.C.-based Atsena Therapeutics. Wellman is the Chief Operating Officer of Akouos, Inc., a precision genetic medicine company. Prior to Akouos, Wellman was Head of Product Development Strategy at Spark Therapeutics, Inc., now a subsidiary of Roche Holding AG, where she was also a co-founder. Previously, Wellman was the Director of Regulatory Affairs for the Center for Cellular and Molecular Therapeutics at Childrens Hospital of Philadelphia.

Eleusis London-based Eleusis tapped four members for its board of directors. David Socks, former CEO of Phathom Pharmaceuticals, joined as chairman of the board. Robert Hershberg, former CBO and CSO of Celgene; John Tucker, CEO of SC Pharmaceuticals; and Esther van den Boom, Managing Partner at van den Boom & Associates also joined.

H1 New York-based H1 announced Mohak Shah has joined the company as SVP of Data Science and Learning. Before joining H1, he was the Vice President of AI and ML at LG Electronics, and prior to that was the Head of Data Science at Bosch.

Renovacor Jiwen Zhang was named senior vice president of regulatory affairs and quality assurance at Philadelphia-based Renovacor, Inc. She most recently served as vice president, head of regulatory affairs at Passage Bio, Inc., an AAV-based gene therapy company. Prior to her time at Passage Bio, Zhang worked as executive director, head of regulatory affairs at Tmunity Therapeutics, Inc. Zhang also previously worked at GE Healthcare and was responsible for building a regulatory affairs function to support the companys newly formed cell technology and regenerative medicine business. Before joining GE Healthcare, Zhang held roles of increasing responsibility at several companies including Merck and Co. Inc., Wyeth Pharmaceuticals (now Pfizer) and Sanofi.

Opiant Pharmaceuticals Matthew Ruth was named Chief Commercial Officer of Opiant Pharmaceuticals. From 2015 until 2019,Ruthwas responsible for building out theU.S.Operational, Commercial, Government Affairs and Medical Affairs team in preparation for the launch and commercialization of Opiants branded nasal naloxone spray. Prior to his work in the opioid overdose space,Ruthwas Chief Operating Officer for RightCare Solutions, a medical technology company. Earlier in his career,Ruthwas Vice President of Azur Pharma. From 2006 to 2007, he was Vice President forAvanir Pharmaceuticals. Prior to that, he held positions of increasing responsibility at Allergan.

Glytec Jordan Messler was named CMO of Waltham, Mass.-based Glytec. In this new role, Messler will be responsible for spearheading continuous improvement initiatives for Glytecs clinical strategy and product development while supporting the delivery, customer, quality and regulatory teams to ensure ethical and safe glycemic management best practices. Messler joined Glytec in October 2018 as the Executive Director of Clinical Practice. Before Glytec, he was the Medical Director for the Morton Plant Hospitalist group.

T-knife Therapeutics Megan Baierlein was named COO of Bay Area-based T-knife. Baierlein was most recently the senior vice president and COO at Audentes Therapeutics, overseeing program management, clinical operations, and general and administrative functions. Prior to Audentes, Baierlein served as executive director of program management at Ultragenyx Pharmaceutical, Inc. Before that, she held management positions at BioMarin in both program management and clinical operations. Earlier in her career, Baierlein held roles of increasing responsibility at Genentech and Elan Pharmaceuticals.

Ji Xing Pharmaceuticals Shanghai-based Ji Xing tapped Joseph Romanelli as CEO. Romanelli has more than 25 years of biopharmaceutical and biotechnology experience, nearly all with Merck & Co., Inc. Most recently, he served as the President of MSD China for more than four years, where he oversaw over 20 product launches, including Keytruda and Gardasil. From an industry and organizational perspective, he was named a Top Ten Pharma Leader of the Year in 2019 by the National Healthy China Forum and managed the companys more than 5,000 employees in the market. He also briefly served as President of U.S. Human Health at Merck overseeing the companys largest market by revenue. Previously, Romanelli held senior roles, including Vice President of Investor Relations.

Hillstream BioPharma Scott J. Dixon, Associate Professor of Biology at Stanford University and Faculty Fellow of Stanfords ChEM-H initiative and Member at Stanford Cancer Institute, joined the Scientific Advisory Board of Hillstream BioPharma.

Certara Nicolette D. Sherman was named Chief Human Resources Officer at Certara. Most recently, Sherman was CHRO at Oyster Point Pharma. Prior to that, she served in multiple roles at Sanofi for 12 years, including Vice President of North American Human Resources Operations and Vice President of Global Leadership Development.

BeyondSpring Brendan Delaney, the Chief Commercial Officer of Constellation Pharma, was appointed to the BeyondSpring Board of Directors. Prior to joining Constellation, Delaney was the CCO at Immunomedics, where he led the buildout of the marketing, sales, market access and commercial operations teams. Previously, he served as Vice President of U.S. Hematology-Oncology at Celgene Corporation. Prior to joining Celgene, he held various commercial roles at both Novartis Oncology and Genentech, where he led several successful product launches for blockbuster brands.

Cygnal Therapeutics Timothy Zheng joined Cygnal Therapeutics as Senior Vice President ofBiology. Zheng joins Cygnal from Boehringer Ingelheim, where he was a Highly Distinguished Research Fellow. He also served as a Member of the U.S. Research Site Leadership Committee and as Executive Director, Immune Modulation. Prior to Boehringer Ingelheim, he held a number of roles at Biogen and Biogen Idec over a 17-year period with increasing responsibilities, most recently as Director of Immunology and then Director of Neuroimmunology.

Byondis Timo van den Berg was named Senior Director of Immuno-Oncology R&D at Netherlands-based Byondis BV. Most recently he serves as head and principal investigator, Immunotherapy Laboratory, Department of Molecular Hematology at Sanquin Research, a non-profit organization responsible for the blood supply in the Netherlands. Since 2017, Van den Berg has been professor of Immunotherapy at Vrije Universiteit. Van den Berg is a member of many boards, including Amsterdam Infection and Immunity Institute and Cancer Center Amsterdam.

FINN Partners Kristie Kuhl was promoted to managing partner, Global Health Practice Leader for FINN Partners, an industry media organization. Kuhl joined Finn Partners in 2015 as U.S. Pharma and NY Health Head. She came to FINN after serving as an executive vice president at agencies Cohn & Wolfe and Makovsky, where she drew on her knowledge of pharma marketing, regulatory law, patient advocacy and the U.S. reimbursement system to advance breakthrough therapies.

Visit link:
Movers & Shakers, July 16 | BioSpace - BioSpace

Esoteric testing is the analysis of 'rare' molecules or substances. It is not performed in a routine clinical laboratory. These test are performed when there is requirement of additional information external routine lab testing, for proper diagnosis of disease, establish a prognosis or select and supervise a therapeutic treatment. Esoteric testing requires skilled personnel to perform the test and analyze the results due to usage of sophisticated chemicals and instruments. The tests are performed by specialized and independent clinical reference laboratories owing to high cost. It is not feasible for physician office laboratories and hospitals to perform these tests in-house. The test are regulated by regulatory stringent regulatory framework. These tests are not performed regularly.

Request Brochure of Report @

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=30377

Based on test type, the global esoteric testing market has been segmented into genetics, endocrinology, immunology, molecular diagnostics, microbiology, oncology, serology, and toxicology. Molecular diagnostics is the fastest growing segment of the market, followed by the immunology and oncology segments, owing to increased prevalence of rare and genetic diseases and high demand for personalized medicine treatment. In terms of technology, the esoteric testing market has been segmented into chemiluminescence, ELISA, mass spectrometry, real time PCR, and flow cytometry. The chemiluminescence segment is expected to witness strong growth, followed by ELISA, because it is the most widely used technology in esoteric testing due to high efficiency and small sample required for testing. The real time PCR segment is expected to be driven by rise in prevalence of genetic disease and increase in demand for genetic testing. Growing use of information technology has allowed instant and efficient data transfer. These developments will provide more efficient results and improved patient care creates huge demand for esoteric testing market. Complex diseases difficult to diagnose and treat through conventional methods are diagnosed using esoteric testing. Rising prevalence of such complex and rare medical diseases is expected to contribute to the growth of the esoteric testing market. Additionally, high investments in proteomics, increasing demand for personalized medicine, and genomics boost the growth of the esoteric testing market. However, stringent government regulations and dearth of qualified and trained professionals are likely to restrain the esoteric testing market.

Request for Analysis of COVID-19 Impact on Esoteric Testing Market @

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=30377

In terms of region, the global esoteric testing market can be classified into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the esoteric testing market, followed by Europe, due to higher incidence and prevalence rate, growing awareness about early disease detection, and quick adoption of sophisticated instruments. Asia Pacific is an emerging market for esoteric testing due to increasing prevalence of disease, gradual development of medical infrastructure, rising awareness, and significant patient pool with unmet medical needs. However, high cost, lack of availability of trained personnel, and poor patient awareness are factors restraining the esoteric testing market in regions such as Middle East & Africa and Latin America.

Pre Book Esoteric Testing Market Report at @

https://www.transparencymarketresearch.com/checkout.php?rep_id=30377&ltype=S

Major players operating in the esoteric testing market include Laboratory Corporation of America Holdings, OPKO Health, Inc., ARUP Laboratories, Genomic Health, Inc., Quest Diagnostics, American Medical Laboratories, Gold Standard Diagnostics Corp, and ZeptoMetrix Corporation.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

Original post:
Esoteric Testing Market: Chemiluminescence segment is expected to witness strong growth - BioSpace

MENLO PARK, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB)(Pacific Biosciences or PacBio), a leading provider of high-quality, long-read sequencing platforms, and Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced an intent to expand their multi-year collaboration to develop a production-scale high-throughput HiFi sequencing platform to include the sequencing technology developed by Omniome, Inc.

The expansion of the collaboration is expected to add the short read sequencing technology enabled by Sequencing by Binding (SBB) chemistry upon close of PacBios proposed acquisition of Omniome, and contingent upon PacBios and Invitaes agreement of associated terms. Omniomes novel and highly differentiated sequencing technology promises significant improvement in raw base accuracy over traditional next generation sequencing products enabling the potential for more precise and sensitive molecular diagnostics. PacBio and Invitae intend to work together to leverage the improved accuracy and sensitivity of SBB chemistry to further advance cancer diagnostics and pathogen detection. Additionally, the parties intend to work together to explore novel methods of integrating SBB chemistry with PacBios HiFi genomes.

We believe access to both of these technologies will accelerate the adoption of long read sequencing techniques in clinical whole genome applications, providing deeper insight into the genome and lower the overall cost of analysis, said Christian Henry, CEO and President at PacBio. Scientists and clinicians rely on accurate short reads and accurate long reads to conduct their science and answer their specific questions. We seek to deliver the most advanced sequencing solutions and are excited that we might expand our development collaboration with Invitae to broadly enable their clinical NGS sequencing.

In partnering with the PacBio team, we are pleased with our progress toward a new generation of innovative whole genome-based offerings, and look forward to expanding that effort to include the highly differentiated SBB chemistry, said Sean George, Co-Founder, President and Chief Executive Officer of Invitae. By combining SBB with PacBios HiFi Sequencing, the opportunity and utility of next generation sequencing technologies can be expanded for patients in the clinical setting with improvement in accuracy and reduction in costs.

The expansion of the collaboration is expected to begin in the second half of 2021 once PacBios acquisition of Omniome, Inc. is complete.

About Pacific BiosciencesPacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing. The companys innovative instruments are based on Single Molecule, Real-Time (SMRT) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism. Cited in thousands of peer-reviewed publications, PacBio sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology. For more information, please visit http://www.pacb.com and follow @PacBio.

About InvitaeInvitae Corporation (NYSE: NVTA) is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitaes goal is to aggregate the worlds genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the companys website at invitae.com.

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

Forward-Looking Statements This press release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995, including statements relating to the intended expansion of the collaboration between PacBio and Invitae to include Omniomes short read sequencing technology, including the expected timing of such expansion; the potential for PacBio to enable Invitaes clinical NGS sequencing capabilities; PacBio and Invitae agreeing to associated terms of such collaboration expansion; the potential cost reductions, and potential increases in accuracy and sensitivity, associated with the use of SBB technology; the potential use of SBB technology for more precise and sensitive molecular diagnostics, including cancer diagnostics and pathogen detection; potential novel methods of integrating SBB chemistry with PacBios HiFi genomes; expectations that access to both SBB and HiFi sequencing technologies may accelerate adoption of long read sequencing techniques in clinical whole genome applications; expectations regarding the timing of the closing of PacBios proposed acquisition of Omniome, and increase the rate of identification of, potential disease-causing genetic variants in rare disease the potential of HiFi data, the applications, insights, and attributes of SMRT sequencing technology, and the benefits of PacBio sequencing. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to the following cautionary statements. All forward-looking statements speak only as of the date of this press release and are based on current expectations and involve a number of assumptions, risks and uncertainties that could cause the actual results to differ materially from such forward-looking statements. Readers are strongly encouraged to read the full cautionary statements contained in the Companys filings with the Securities and Exchange Commission, including the risks set forth in the companys Forms 8-K, 10-K, and 10-Q. The Company disclaims any obligation to update or revise any forward-looking statements.

Contacts

Investors:Todd Friedman+1 (650) 521-8450ir@pacificbiosciences.com

Media:Jen Carroll+1 (858) 449-8082pr@pacificbiosciences.com

Read more:
Pacific Biosciences and Invitae Announce Intent to Expand Collaboration - BioSpace